Recipients with blood group A associated with longer survival rates in cardiac valvular bioprostheses.
ABO Blood-Group System
Adolescent
Adult
Aged
Aged, 80 and over
Animals
Cattle
Child
Female
France
/ epidemiology
Health Surveys
Heart Valve Prosthesis Implantation
/ adverse effects
Humans
Longevity
Male
Middle Aged
Postoperative Complications
Prognosis
Registries
Survival Rate
Swine
Transplant Recipients
Young Adult
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
03
12
2018
revised:
12
02
2019
accepted:
20
02
2019
pubmed:
18
3
2019
medline:
21
8
2019
entrez:
18
3
2019
Statut:
ppublish
Résumé
Pigs/bovines share with humans some of the antigens present on cardiac valves. Two such antigens are: the major xenogenic Ag, "Gal" present in all pig/bovine very close to human B-antigen of ABO-blood-group system; the minor Ag, pig histo-blood-group AH-antigen identical to human AH-antigen and present by some animals. We hypothesize that these antigens may modify the immunogenicity of the bioprosthesis and also its longevity. ABO distribution may vary between patients with low (<6 years) and high (≥15 years) bioprostheses longevity. Single-centre registry study (Paris, France) including all degenerative porcine bioprostheses (mostly Carpentier-Edwards 2nd/3rd generation heart valves) explanted between 1985 and 1998 and some bovine bioprostheses. For period 1998-2014, all porcine bioprostheses with longevity ≥13 years (follow-up ≥29 years). Important predictive factors for bioprosthesis longevity: number, site of implantation, age were collected. Blood group and other variables were entered into an ordinal logistic regression analysis model predicting valve longevity, categorized as low (<6 years), medium (6-14.9 years), and high (≥15 years). Longevity and ABO-blood group were obtained for 483 explanted porcine bioprostheses. Mean longevity was 10.2 ± 3.9 years [0-28] and significantly higher for A-patients than others (P = 0.009). Using multivariate analysis, group A was a strong predictive factor of longevity (OR 2.09; P < 0.001). For the 64 explanted bovine bioprosthesis with low/medium longevity, the association, with A-group was even more significant. Patients of A-group but not B have a higher longevity of their bioprostheses. Future graft-host phenotyping and matching may give rise to a new generation of long-lasting bioprosthesis for implantation in humans, especially for the younger population. FUND: None.
Sections du résumé
BACKGROUND
BACKGROUND
Pigs/bovines share with humans some of the antigens present on cardiac valves. Two such antigens are: the major xenogenic Ag, "Gal" present in all pig/bovine very close to human B-antigen of ABO-blood-group system; the minor Ag, pig histo-blood-group AH-antigen identical to human AH-antigen and present by some animals. We hypothesize that these antigens may modify the immunogenicity of the bioprosthesis and also its longevity. ABO distribution may vary between patients with low (<6 years) and high (≥15 years) bioprostheses longevity.
METHODS
METHODS
Single-centre registry study (Paris, France) including all degenerative porcine bioprostheses (mostly Carpentier-Edwards 2nd/3rd generation heart valves) explanted between 1985 and 1998 and some bovine bioprostheses. For period 1998-2014, all porcine bioprostheses with longevity ≥13 years (follow-up ≥29 years). Important predictive factors for bioprosthesis longevity: number, site of implantation, age were collected. Blood group and other variables were entered into an ordinal logistic regression analysis model predicting valve longevity, categorized as low (<6 years), medium (6-14.9 years), and high (≥15 years).
FINDINGS
RESULTS
Longevity and ABO-blood group were obtained for 483 explanted porcine bioprostheses. Mean longevity was 10.2 ± 3.9 years [0-28] and significantly higher for A-patients than others (P = 0.009). Using multivariate analysis, group A was a strong predictive factor of longevity (OR 2.09; P < 0.001). For the 64 explanted bovine bioprosthesis with low/medium longevity, the association, with A-group was even more significant.
INTERPRETATION
CONCLUSIONS
Patients of A-group but not B have a higher longevity of their bioprostheses. Future graft-host phenotyping and matching may give rise to a new generation of long-lasting bioprosthesis for implantation in humans, especially for the younger population. FUND: None.
Identifiants
pubmed: 30878598
pii: S2352-3964(19)30126-4
doi: 10.1016/j.ebiom.2019.02.047
pmc: PMC6491382
pii:
doi:
Substances chimiques
ABO Blood-Group System
0
Types de publication
Journal Article
Langues
eng
Pagination
54-63Informations de copyright
Copyright © 2019. Published by Elsevier B.V.
Références
Br J Haematol. 1999 Apr;105(1):110-6
pubmed: 10233372
Blood. 1999 Jun 15;93(12):4418-24
pubmed: 10361140
Xenotransplantation. 1999 Aug;6(3):173-80
pubmed: 10503783
Kidney Int. 2000 Feb;57(2):655-63
pubmed: 10652044
Glycobiology. 2000 Jun;10(6):611-21
pubmed: 10814703
Circulation. 2001 Mar 20;103(11):1535-41
pubmed: 11257081
Blood. 2001 May 15;97(10):3308-10
pubmed: 11342465
Ann Thorac Surg. 2001 May;71(5 Suppl):S224-7
pubmed: 11388191
Anim Genet. 2001 Jun;32(3):132-8
pubmed: 11493261
J Thorac Cardiovasc Surg. 2003 Feb;125(2):306-14
pubmed: 12579099
Cardiovasc Pathol. 2003 May-Jun;12(3):119-39
pubmed: 12763552
J Thromb Haemost. 2003 Jan;1(1):33-40
pubmed: 12871537
Ann N Y Acad Sci. 1962 May 3;97:205-25
pubmed: 13861461
Xenotransplantation. 2004 Jul;11(4):376-7
pubmed: 15196133
J Am Coll Cardiol. 2004 Jul 21;44(2):384-8
pubmed: 15261935
Exp Gerontol. 2004 Oct;39(10):1563-5
pubmed: 15501027
Nat Med. 2005 Jan;11(1):29-31
pubmed: 15619628
Eur J Clin Invest. 2005 Jan;35(1):17-23
pubmed: 15638815
Transplant Proc. 1992 Apr;24(2):445-6
pubmed: 1566382
Transfusion. 2005 May;45(5):779-87
pubmed: 15847669
Immunol Cell Biol. 2005 Aug;83(4):396-404
pubmed: 16033535
Xenotransplantation. 2006 May;13(3):186-94
pubmed: 16756561
Tissue Antigens. 2006 Dec;68(6):459-66
pubmed: 17176435
Cell. 2007 Sep 21;130(6):971-4
pubmed: 17889638
Nat Med. 2007 Oct;13(10):1165-8
pubmed: 17917666
Semin Immunol. 2008 Apr;20(2):109-16
pubmed: 18083531
J Card Surg. 1991 Dec;6(4 Suppl):589-94
pubmed: 1810551
Circulation. 2008 Jan 15;117(2):253-6
pubmed: 18195186
J Am Coll Cardiol. 2008 Sep 23;52(13):e1-142
pubmed: 18848134
Ann Thorac Surg. 2009 Jan;87(1):211-4
pubmed: 19101299
Curr Opin Organ Transplant. 2009 Apr;14(2):154-60
pubmed: 19300259
J Mol Evol. 2009 Jul;69(1):22-31
pubmed: 19533213
Transplant Proc. 2009 Jun;41(5):1921-6
pubmed: 19545757
Tissue Eng Part A. 2009 Dec;15(12):3877-88
pubmed: 19563260
PLoS Pathog. 2009 Jul;5(7):e1000504
pubmed: 19578439
Expert Opin Biol Ther. 2009 Aug;9(8):1017-29
pubmed: 19591628
Histopathology. 2009 Aug;55(2):135-44
pubmed: 19694820
J Heart Lung Transplant. 2010 May;29(5):538-43
pubmed: 20036160
Xenotransplantation. 2010 Jan-Feb;17(1):48-60
pubmed: 20149188
Xenotransplantation. 2010 Jan-Feb;17(1):61-70
pubmed: 20149189
J Heart Valve Dis. 2010 Jan;19(1):124-30
pubmed: 20329498
Ann Thorac Surg. 2010 May;89(5):1410-6
pubmed: 20417753
Transplantation. 1991 Jun;51(6):1290-5
pubmed: 2048201
Xenotransplantation. 2010 May-Jun;17(3):197-206
pubmed: 20636540
Nat Rev Cardiol. 2010 Dec;7(12):711-9
pubmed: 21045786
J Thorac Cardiovasc Surg. 2011 Jan;141(1):269-75
pubmed: 21168032
Anim Genet. 2011 Jun;42(3):325-8
pubmed: 21554350
J Thorac Cardiovasc Surg. 2012 Jul;144(1):108-11
pubmed: 21864857
Cell Reprogram. 2012 Aug;14(4):353-63
pubmed: 22775484
Am Heart J. 2012 Aug;164(2):177-85
pubmed: 22877802
Cardiovasc Pathol. 2013 Jul-Aug;22(4):251-6
pubmed: 23290353
Xenotransplantation. 2013 Jul-Aug;20(4):252-61
pubmed: 23865597
Xenotransplantation. 2013 Sep-Oct;20(5):277-91
pubmed: 24033743
J Heart Valve Dis. 2013 May;22(3):383-90
pubmed: 24151765
Circ Cardiovasc Genet. 2014 Feb;7(1):43-8
pubmed: 24395926
J Tissue Eng Regen Med. 2015 May;9(5):504-11
pubmed: 24668694
J Biol Chem. 1989 Aug 25;264(24):14290-7
pubmed: 2503516
Thromb Haemost. 2014 Dec;112(6):1103-9
pubmed: 25187297
Sci Rep. 2014 Oct 13;4:6601
pubmed: 25307962
Immun Ageing. 2014 Nov 01;11:16
pubmed: 25512760
Ann Thorac Surg. 2015 Mar;99(3):831-7
pubmed: 25583467
BMC Med. 2015 Jan 15;13:8
pubmed: 25592833
Ann Thorac Surg. 2015 Apr;99(4):1239-47
pubmed: 25662439
Dev Dyn. 2016 Mar;245(3):307-22
pubmed: 26638186
Biomaterials. 2016 Apr;86:68-82
pubmed: 26890039
Eur J Cardiothorac Surg. 2016 Oct;50(4):605-616
pubmed: 27026750
Acta Biomater. 2016 Sep 1;41:204-9
pubmed: 27268480
Xenotransplantation. 2016 Jul;23(4):279-92
pubmed: 27373998
Anatol J Cardiol. 2016 Nov;16(11):820-823
pubmed: 27488753
Ann Thorac Surg. 1989 Jul;48(1):54-9
pubmed: 2764601
ACS Chem Biol. 2017 May 19;12(5):1288-1296
pubmed: 28294600
J Am Coll Cardiol. 2017 May 2;69(17):2193-2211
pubmed: 28449781
Sci Rep. 2017 May 26;7(1):2446
pubmed: 28550302
PLoS One. 2017 Jul 17;12(7):e0180768
pubmed: 28715486
J Am Coll Cardiol. 2017 Aug 22;70(8):1013-1028
pubmed: 28818190
Eur J Cardiothorac Surg. 2017 Sep 1;52(3):408-417
pubmed: 28874031
Gene. 2018 Jan 15;640:1-5
pubmed: 28966132
Glob Cardiol Sci Pract. 2016 Dec 30;2016(4):e201632
pubmed: 28979902
Circulation. 2018 Jan 23;137(4):388-399
pubmed: 29358344
J Virol. 2018 Apr 13;92(9):
pubmed: 29467317
Acta Biomater. 2018 May;72:196-205
pubmed: 29631050
J Card Surg. 1988 Sep;3(3 Suppl):359-68
pubmed: 2980038
Am J Cardiol. 2018 Aug 1;122(3):413-419
pubmed: 29958715
Acta Biomater. 2018 Oct 1;79:253-264
pubmed: 30130615
Circulation. 1985 Sep;72(3 Pt 2):II140-5
pubmed: 4028358
J Am Coll Cardiol. 1985 Nov;6(5):1149-54
pubmed: 4045039
Transpl Int. 1994;7(6):405-13
pubmed: 7532414
Ann Thorac Surg. 1995 Aug;60(2 Suppl):S292-5; discussion S295-6
pubmed: 7646175
J Pediatr. 1994 Jul;125(1):87-91
pubmed: 8021795
Transplantation. 1997 Aug 15;64(3):546-9
pubmed: 9275130
Ann Thorac Surg. 1998 Dec;66(6 Suppl):S82-7
pubmed: 9930423